27131339|t|HERG1 potassium channel expression in potentially malignant disorders of the oral mucosa and prognostic relevance in oral squamous cell carcinoma
27131339|a|HERG1 potassium channel plays a critical role in the cell proliferation. HERG1 protein expression was analyzed by immunohistochemistry (IHC) in 62 patients with oral leukoplakias and 100 patients with oral squamous cell carcinomas (OSCC). HERG1 mRNA levels were assessed by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) in 22 patients with primary head and neck squamous cell carcinoma (HNSCC). Statistically significant associations were found between HERG1 expression and tobacco consumption, disease stage, tumor differentiation, tumor recurrence, and reduced survival. There was no association between HERG1 expression and the risk of progression from oral leukoplakia to OSCC. In addition, a high proportion of tumors (80%) showed increased HERG1 mRNA levels compared to normal mucosa from nononcologic patients. Aberrant HERG1 expression increases as oral tumorigenesis progresses from oral hyperplasia to OSCC. Increased HERG1 mRNA levels were also frequently detected in OSCC and other HNSCC subsites. HERG1 expression emerges as a clinically relevant feature during tumor progression and a potential poor prognostic biomarker for OSCC. Â© 2016 Wiley Periodicals, Inc. Head Neck 38: 1708-1716, 2016.
27131339	0	5	HERG1	T116,T123	C1566128
27131339	6	23	potassium channel	T116,T123	C0032824
27131339	24	34	expression	T045	C1171362
27131339	38	49	potentially	T080	C3245505
27131339	50	69	malignant disorders	T191	C0006826
27131339	77	88	oral mucosa	T023	C0026639
27131339	93	103	prognostic	T170	C0220901
27131339	104	113	relevance	T080	C2347946
27131339	117	145	oral squamous cell carcinoma	T191	C0585362
27131339	146	151	HERG1	T116,T123	C1566128
27131339	152	169	potassium channel	T116,T123	C0032824
27131339	178	186	critical	T080	C1511545
27131339	187	191	role	T077	C1705810
27131339	199	217	cell proliferation	T043	C0596290
27131339	219	232	HERG1 protein	T116,T123	C1566128
27131339	233	243	expression	T045	C1171362
27131339	248	256	analyzed	T062	C0936012
27131339	260	280	immunohistochemistry	T060	C0021044
27131339	282	285	IHC	T060	C0021044
27131339	293	301	patients	T101	C0030705
27131339	307	324	oral leukoplakias	T191	C0023532
27131339	333	341	patients	T101	C0030705
27131339	347	376	oral squamous cell carcinomas	T191	C0585362
27131339	378	382	OSCC	T191	C0585362
27131339	385	390	HERG1	T028	C1416571
27131339	391	395	mRNA	T114,T123	C0035696
27131339	396	402	levels	T080	C0441889
27131339	408	416	assessed	T052	C1516048
27131339	420	477	real-time reverse transcriptase-polymerase chain reaction	T063	C0599161
27131339	479	485	RT-PCR	T063	C0599161
27131339	493	501	patients	T101	C0030705
27131339	507	514	primary	T080	C0205225
27131339	515	552	head and neck squamous cell carcinoma	T191	C1168401
27131339	554	559	HNSCC	T191	C1168401
27131339	562	587	Statistically significant	T081	C0237881
27131339	588	600	associations	T080	C0439849
27131339	620	625	HERG1	T116,T123	C1566128
27131339	626	636	expression	T045	C1171362
27131339	641	660	tobacco consumption	T055	C0543414
27131339	662	675	disease stage	T060	C0699749
27131339	677	682	tumor	T191	C0027651
27131339	683	698	differentiation	T043	C0007589
27131339	700	716	tumor recurrence	T191	C0521158
27131339	722	729	reduced	T080	C0392756
27131339	730	738	survival	T052	C0038952
27131339	750	752	no	T169	C1518422
27131339	753	764	association	T080	C0439849
27131339	773	778	HERG1	T116,T123	C1566128
27131339	779	789	expression	T045	C1171362
27131339	798	802	risk	T078	C0035647
27131339	806	817	progression	T191	C0178874
27131339	823	839	oral leukoplakia	T191	C0023532
27131339	843	847	OSCC	T191	C0585362
27131339	864	868	high	T080	C0205250
27131339	869	879	proportion	T081	C1709707
27131339	883	889	tumors	T191	C0027651
27131339	903	912	increased	T081	C0205217
27131339	913	918	HERG1	T028	C1416571
27131339	919	923	mRNA	T114,T123	C0035696
27131339	924	930	levels	T080	C0441889
27131339	931	939	compared	T052	C1707455
27131339	943	956	normal mucosa	T024	C0026724
27131339	962	983	nononcologic patients	T101	C0030705
27131339	985	993	Aberrant	T080	C0443127
27131339	994	999	HERG1	T116,T123	C1566128
27131339	1000	1010	expression	T045	C1171362
27131339	1011	1020	increases	T169	C0442805
27131339	1029	1053	tumorigenesis progresses	T191	C0178874
27131339	1059	1075	oral hyperplasia	T046	C1400010
27131339	1079	1083	OSCC	T191	C0585362
27131339	1085	1094	Increased	T081	C0205217
27131339	1095	1100	HERG1	T028	C1416571
27131339	1101	1105	mRNA	T114,T123	C0035696
27131339	1106	1112	levels	T080	C0441889
27131339	1134	1142	detected	T033	C0442726
27131339	1146	1150	OSCC	T191	C0585362
27131339	1161	1166	HNSCC	T191	C1168401
27131339	1167	1175	subsites	T082	C1710234
27131339	1177	1182	HERG1	T116,T123	C1566128
27131339	1183	1193	expression	T045	C1171362
27131339	1207	1217	clinically	T080	C0205210
27131339	1218	1226	relevant	T080	C2347946
27131339	1227	1234	feature	T080	C2348519
27131339	1242	1259	tumor progression	T191	C0178874
27131339	1266	1275	potential	T080	C3245505
27131339	1276	1280	poor	T080	C2700379
27131339	1281	1291	prognostic	T170	C0220901
27131339	1292	1301	biomarker	T201	C0005516
27131339	1306	1310	OSCC	T191	C0585362